Pharmacokinetics of Novel Atrial‐Selective Antiarrhythmic Agent Vernakalant Hydrochloride Injection (RSD1235): Influence of CYP2D6 Expression and Other Factors
Explore this paper's citation graph
Summary
The results suggest that an assessment of CYP2D6 expression may not be needed when vernakalant is administered acutely and intravenously to patients with atrial fibrillation.
- Type
- article
- Published
- 2009-01-01
- Cited by
- 40
- References
- 24
- OpenAlex
- https://openalex.org/W2085955843
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:23157076
Keywords
Pharmacology, Pharmacokinetics, CYP2D6, Antiarrhythmic agent, Medicine
References
- Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6.
- Polymorphic dextromethorphan metabolism: Co‐segregation of oxidative O‐demethylation with debrisoquin hydroxylation
- Midterm Results After Stentless Mitral Valve Replacement
- The Framingham study.
- Polymorphism of CYP2D6 in Black populations: implications for psychopharmacology.
- Pharmacogenetics of the cytochromes P450.
- Glucuronidation of Drugs
- Review : Heterogeneity of cytochrome P450 and its toxicological significance
- Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication
- Geographical/Interracial Differences in Polymorphic Drug Oxidation
- Hemodynamic changes after cardioversion of chronic atrial fibrillation.
- The Mechanism of Atrial Antiarrhythmic Action of RSD1235
- The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in Humans
- Vernakalant Hydrochloride for Rapid Conversion of Atrial Fibrillation: A Phase 3, Randomized, Placebo-Controlled Trial
- A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.
- Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.
- Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
- Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.
- Atrial fibrillation as a contributing cause of death and Medicare hospitalization--United States, 1999.
Cited by
- Pharmacotherapy Options in Atrial Fibrillation: Focus on Vernakalant
- Vernakalant: A novel agent for the termination of atrial fibrillation.
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance
- Population pharmacokinetic–pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter
- Vernakalant: A New Drug to Treat Patients With Acute Onset Atrial Fibrillation
- Novel Approaches for Pharmacological Management of Atrial Fibrillation
- Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
- The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.
- The pharmaceutical pipeline for atrial fibrillation
- Population Pharmacokinetics of Vernakalant Hydrochloride Injection (RSD1235) in Patients With Atrial Fibrillation or Atrial Flutter
- Spotlight on Intravenous Vernakalant in Recent-Onset Atrial Fibrillation
- Clinical Update on the Management of Atrial Fibrillation
- Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis
- Vernakalant hydrochloride in the treatment of atrial fibrillation: a review of the latest clinical evidence
- Pharmacokinetics/Pharmacodynamics of Antiarrhythmic Drugs.
- Vernakalant hydrochloride to treat atrial fibrillation
- Efficacy and Safety of Vernakalant in Recent‐Onset Atrial Fibrillation After the European Medicines Agency Approval: Systematic Review and Meta‐Analysis
- New antiarrhythmic drugs for treatment of atrial fibrillation.
- Antiarrhythmic effect of vernakalant in electrically remodeled goat atria is caused by slowing of conduction and prolongation of postrepolarization refractoriness.
- New anthyarrhythmic drugs for atrial fibrillation.
Related papers
- The increasing doses of methotrexate pharmacokinetics after intravenous administration in rats - model selection
- Pharmacokinetics of monoclonal antibody HAb 18 and its F(ab^)_(2) and fab fragments in mice
- Pharmacokinetics of 2',3'-dideoxyinosine in monkeys
- Use of physiological based pharmacokinetic modeling for cross-species prediction of pharmacokinetic and tissue distribution profiles of a novel niclosamide prodrug
- Application of Physiologically Based Pharmacokinetic Modeling to Understanding the Clinical Pharmacokinetics of UK-369,003
- Effects of CYP2D6 Genetic Polymorphism and Drug Interaction on the Metabolism of Dacomitinib.
- Effects of Animal Strain, Dose, and Cotreatment with Saikosaponin b2 on the Pharmacokinetics of Saikosaponin a in Rats
- Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters
- Pharmacokinetic modelling of pentoxifylline and lisofylline after oral and intravenous administration in mice